Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elpivirine
- Development stage
- Unknown
- Lead developer
- Viriom
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Elpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) developed for the treatment and prevention of HIV-1 infection. Originally discovered by Roche and subsequently licensed to Viriom Inc. in 2009, the drug is designed to inhibit the reverse transcriptase enzyme of HIV-1, thereby preventing viral replication. Elpivirine is characterized by a high genetic barrier to resistance and a favorable safety profile compared to earlier NNRTIs. It is currently marketed in Russia under the brand name Elpida and is undergoing global clinical development in various formulations, including fixed-dose combinations and long-acting injectable formulations, to improve patient adherence and address the challenges of chronic HIV management.
- Brand names
- Elpida
- Other names
- Elpivirine
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on elpivirine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elpivirine.